title: Screening of Newborns for Disorders with High Benefit-Risk Ratios Should Be Mandatory.
abstract: Newborn screening has evolved to include an increasingly complex spectrum of diseases, raising concerns that screening should be optional and require parental consent. Early detection of disorders like PKU and MCAD is essential to prevent serious disability and death in affected children. These are examples of high benefit-risk ratio disorders because of the irrefutable health benefits of early detection, coupled with the low risks of treatment. The dire consequences of not diagnosing an infant with a treatable disorder because of parental refusal to screen are wholly unacceptable. Thus, we believe that newborn screening for disorders with high benefit-risk ratios should continue to be mandatory.
authors.affiliation: Nicole Kelly, M.P.H., is the Research Program Manager for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Albert Einstein College of Medicine. She is the Research Manager for the Division of Pediatric Genetic Medicine at the Children's Hospital at Montefiore. Dalia Chehayeb Makarem, M.P.H., is the Clinical Research Coordinator for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Icahn School of Medicine at Mount Sinai. Melissa P. Wasserstein, M.D., is an Associate Professor of Pediatrics at the Albert Einstein College of Medicine and the Chief of Pediatric Genetic Medicine at The Children's Hospital at Montefiore in the Bronx, NY. She is a clinical biochemical geneticist, specializing in the care of individuals with rare inborn errors of metabolism.
authors.forename: Nicole
authors.initials: N
authors.lastname: Kelly
authors.affiliation: Nicole Kelly, M.P.H., is the Research Program Manager for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Albert Einstein College of Medicine. She is the Research Manager for the Division of Pediatric Genetic Medicine at the Children's Hospital at Montefiore. Dalia Chehayeb Makarem, M.P.H., is the Clinical Research Coordinator for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Icahn School of Medicine at Mount Sinai. Melissa P. Wasserstein, M.D., is an Associate Professor of Pediatrics at the Albert Einstein College of Medicine and the Chief of Pediatric Genetic Medicine at The Children's Hospital at Montefiore in the Bronx, NY. She is a clinical biochemical geneticist, specializing in the care of individuals with rare inborn errors of metabolism.
authors.forename: Dalia Chehayeb
authors.initials: DC
authors.lastname: Makarem
authors.affiliation: Nicole Kelly, M.P.H., is the Research Program Manager for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Albert Einstein College of Medicine. She is the Research Manager for the Division of Pediatric Genetic Medicine at the Children's Hospital at Montefiore. Dalia Chehayeb Makarem, M.P.H., is the Clinical Research Coordinator for the Pilot Newborn Screening for Lysosomal Storage Disorders at the Icahn School of Medicine at Mount Sinai. Melissa P. Wasserstein, M.D., is an Associate Professor of Pediatrics at the Albert Einstein College of Medicine and the Chief of Pediatric Genetic Medicine at The Children's Hospital at Montefiore in the Bronx, NY. She is a clinical biochemical geneticist, specializing in the care of individuals with rare inborn errors of metabolism.
authors.forename: Melissa P
authors.initials: MP
authors.lastname: Wasserstein
mesh_terms: D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening; D016017:Odds Ratio; D033282:Parental Consent; D018570:Risk Assessment